Introduction and Objective: Oxytocin has been proposed to have anorexigenic effects and the gene is among the most upregulated in the small intestine after Roux-en-Y gastric bypass (RYGB) surgery. We evaluated oxytocin and oxytocin receptor gene expression along the intestinal tract in individuals with and without type 2 diabetes, and assessed circulating concentrations of the oxytocin carrier molecule, neurophysin I (NP1), before and after RYGB. Methods: Mucosal biopsies obtained at 30-cm intervals along the small intestine and from seven specific sites in the large intestine in 12 individuals with type 2 diabetes and 12 healthy control individuals were analyzed using mRNA sequencing. Serum NP1 levels were measured during four mixed meal tests in 20 overnight fasted individuals three months and one week before and one week and three months after undergoing RYGB surgery for obesity. Results: Oxytocin mRNA was expressed throughout the small intestine and undetectable in the large intestine of both individuals with and without type 2 diabetes. Oxytocin receptor mRNA expression was low throughout the small and large intestines in both groups. Three months after RYGB, fasting and postprandial peak NP1 concentrations decreased compared with pre-RYGB meal tests. Postprandial responses of NP1 assessed by baseline-subtracted area under the curve were modest and similar during all meal tests. Time to peak NP1 concentrations decreased one week after RYGB and normalized within three months. Conclusion: We provide evidence of robust oxytocin mRNA expression throughout the small intestine in individuals with and without type 2 diabetes whereas only little or no expression was observed in the large intestine. Also, we show that postprandial increases in circulating NP1 are modest and that RYGB reduces circulating concentrations of NP1. Disclosure I. Gether: None. H. Gilliam-Vigh: Research Support; Zealand Pharma A/S. V. Kliim-Hansen: None. B. Hartmann: Employee; Bainan Biotech. J.J. Holst: Advisory Panel; Novo Nordisk A/S. Consultant; Novo Nordisk A/S. Other Relationship; Novo Nordisk A/S. Consultant; AstraZeneca, Fractyl Health, Inc., MSD Life Science Foundation, Structure Therapeutics, Inc. A.B. Lund: Consultant; Zealand Pharma A/S. Advisory Panel; Eli Lilly and Company. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim. L.S. Gasbjerg: Stock/Shareholder; Antag Therapeutics, Bainan Biotech. F.K. Knop: Consultant; 89bio, Inc, AstraZeneca. Speaker's Bureau; AstraZeneca. Advisory Panel; Boehringer-Ingelheim. Consultant; Cytoki Pharma. Advisory Panel; Eli Lilly and Company. Consultant; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Research Support; Gubra. Advisory Panel; Novo Nordisk A/S. Consultant; Novo Nordisk A/S. Employee; Novo Nordisk A/S. Research Support; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S, Eli Lilly and Company. Advisory Panel; Sanofi. Consultant; Structure Therapeutics, Inc. Advisory Panel; Zealand Pharma A/S. Consultant; Zealand Pharma A/S. Research Support; Zealand Pharma A/S. Speaker's Bureau; Zealand Pharma A/S. Stock/Shareholder; Zealand Pharma A/S, Gubra. Advisory Panel; Zucara Therapeutics. Consultant; Zucara Therapeutics. Stock/Shareholder; Antag Therapeutics.
Read full abstract- All Solutions
Editage
One platform for all researcher needs
Paperpal
AI-powered academic writing assistant
R Discovery
Your #1 AI companion for literature search
Mind the Graph
AI tool for graphics, illustrations, and artwork
Journal finder
AI-powered journal recommender
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus - Support
Overview
102 Articles
Published in last 50 years
Articles published on Oxytocin Receptor Gene Expression
Authors
Select Authors
Journals
Select Journals
Duration
Select Duration
100 Search results
Sort by Recency